intravitreal injections of ziv-aflibercept (1.25 mg/0.05 mL)	baseline	The mean best-corrected visual acuity (BCVA) at 1 month, and at 4 months	1201	1349	The mean BCVA did not improve significantly from baseline (1.00 LogMAR) to the 1-month (0.74 LogMAR; P=0.2) and 4-month (0.71 LogMAR; P=0.13) visits
intravitreal injections of ziv-aflibercept (1.25 mg/0.05 mL)	baseline	central macular thickness (CMT) at 1 month and at 4 months	1054	1200	he mean ± standard deviation CMT decreased from 604±199 μm at baseline to 319±115 μm (P=0.001) at 1 month and to 351±205 μm (P=0.026) at 4 months.
intravitreal injections of ziv-aflibercept (1.25 mg/0.05 mL)	baseline	The mean best-corrected visual acuity (BCVA) at 1 month, and at 4 months	1201	1350	The mean BCVA did not improve significantly from baseline (1.00 LogMAR) to the 1-month (0.74 LogMAR; P=0.2) and 4-month (0.71 LogMAR; P=0.13) visits.
intravitreal injections of ziv-aflibercept (1.25 mg/0.05 mL)	baseline	central macular thickness (CMT) at 1 month and at 4 months	11628	11751	The mean CMT at baseline (603±199 μm) decreased to 319±115 μm (P=0.001) at 1 month and to 351±205 μm (P=0.026) at 4 months.
intravitreal injections of ziv-aflibercept (1.25 mg/0.05 mL)	baseline	central macular thickness (CMT) at 1 month and at 4 months	1201	1350	The mean BCVA did not improve significantly from baseline (1.00 LogMAR) to the 1-month (0.74 LogMAR; P=0.2) and 4-month (0.71 LogMAR; P=0.13) visits.
